ClinicalTrials.gg
CompletedNCT02144415Updated Apr 13, 2026

A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

A Phase 1 interventional study of EB-1020 400 mg and EB-1020 800 mg in Healthy Volunteers and Drug Users, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Drug Misuse with a site in United States — none open to participants now, none under way, none of them phase 3. Drug Misuse · United States.

Enrollment
9th of 13
80 · median 105
Started
2014
the only one that year
Phase 1
Only one
of the 13
Registered
9th of 13
by date
Lead sponsor
1 of 13
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 13 studies in Drug Misuse with a site in United States, this one is the 9th largest by enrollment, is the only one that started in 2014, is the only one in phase 1, and was the 9th registered.

Drug Misuse

31 studies on the registry are indexed under Drug Misuse; 5 are open to participants now.

Browse Drug Misuse studies →

Open to participants now

None of the 13 studies in Drug Misuse with a site in United States is open now. The open studies under Drug Misuse, anywhere →

Who these studies take

Of the 2 Drug Misuse studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Drug Misuse with a site in United States as a file.
02

Study summary

This single-center study will be a single-dose, randomized, double-blind, placebo- and active-controlled crossover study with a single inpatient treatment visit. The abuse potential of single oral doses of EB-1020 IR (400 mg, 800 mg) will be compared with that of placebo and d-amphetamine (20 mg, 40 mg; active control) in healthy recreational stimulant users. Subjects will participate in a medical Screening visit (Visit 1), one 4-day inpatient Qualification Phase (Visit 2), one 11-day inpatient Treatment Phase (Visit 3), and a safety Follow-up visit (Visit 4).

Read the detailed description

Subjects will be randomized to 1 of 10 treatment sequences according to a two 5 x 5 William squares design. To maintain blinding, subjects will be required to ingest eight capsules with approximately 240 mL water on each study drug administration day.

Serial pharmacodynamic (PD) evaluations will be conducted up to 24 hours after each study drug administration. Pharmacokinetic (PK) samples will be obtained to confirm exposure to EB-1020. Safety monitoring will include recording of adverse events (AEs), regular assessments of vital signs measurements, 12-lead electrocardiogram (ECG) findings, and continuous telemetry monitoring for at least 3 hours after study drug administration.

03

Conditions studied

  • Healthy Volunteers
  • Drug Users

Keywords

  • abuse liability
  • recreational drug user
  • stimulant
  • d-amphetamine
  • ADHD
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be healthy male nondependent recreational drug users
  2. Subjects must be 18 to 55 years old, inclusive.
  3. Subjects must have greater than or equal to 10 lifetime nontherapeutic experiences with central nervous system (CNS) stimulants (e.g., amphetamines, cocaine, methylphenidate), greater than or equal to 1 nontherapeutic use of prescription stimulants within the 12 months prior to Screening, and greater than or equal to 1 nontherapeutic use of a CNS stimulant within the 12 weeks prior to Screening.

Exclusion criteria

Exclusion Criteria:

  1. Subjects that are deemed medically unsuitable or unlikely to comply with the study protocol for any reason.
  2. Subjects who do not pass Qualification Phase criteria to be eligible for the Treatment Phase.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    EB-1020 400 mg

    EB-1020 400 mg, administered as four 100-mg IR capsules and 4 matching placebo capsules

    Drug: EB-1020 400 mg

  • Experimental
    EB-1020 800 mg

    EB-1020 800 mg, administered as eight 100-mg IR capsules

    Drug: EB-1020 800 mg

  • Active comparator
    lisdexamfetamine 150 mg

    lisdexamfetamine 150 mg, administered as 3 capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 matching placebo capsules

    Drug: lisdexamfetamine 150 mg

  • Active comparator
    d-amphetamine 40 mg

    d-amphetamine 40 mg, administered as 4 capsules, each containing two 5-mg d-amphetamine tablets and 4 matching placebo capsules

    Drug: d-amphetamine 40 mg

  • Placebo comparator
    Placebo

    Placebo, administered as 8 matching placebo capsules

    Drug: Placebo

Interventions

  • 4 x EB-1020 100-mg capsules, and 4 matching placebo capsules

  • 8 x EB-1020 100-mg capsules

  • 3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules

  • 4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules

  • DrugPlacebo

    8 x matching placebo capsules

06

What researchers measure

Primary outcomes

  1. Maximum effect (Emax) on Drug Liking visual analog scale (VAS)

    Drug liking VAS is one of the measures of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm).

    Time frame: within 24 hours post-dose

Secondary outcomes

  1. Drug Liking VAS (minimum effect [Emin] and time-averaged area under the effect curve to 12 hours after study drug administration [TA_AUE])

    Drug liking VAS is one of the measures of balance of effects that assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm).

    Time frame: within 24 hours post-dose

  2. Overall Drug Liking VAS (Emax/Emin)

    Overall drug liking VAS is one of the measures of balance of effects that assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carryover effects). A 100 mm bipolar VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = "strong disliking", 50 mm= "neither like nor dislike", and 100 mm= "strong liking").

    Time frame: within 24 hours post-dose

  3. Take Drug Again VAS (Emax)

    Take drug again VAS is one of the measures of balance of effects. It is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm bipolar VAS with score ranging from 0 mm to 100 mm (score of 0 mm = "definitely not", 50 mm = "do not care", and 100 mm = "definitely so").

    Time frame: within 24 hours post-dose

  4. High VAS (Emax and TA_AUE)

    High VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 = definitely so).

    Time frame: within 24 hours post-dose

  5. Good Effects VAS (Emax and TA_AUE)

    Good drug effects VAS is one of the measures of positive effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).

    Time frame: within 24 hours post-dose

  6. Bad Effects VAS (Emax and TA_AUE)

    Bad effects VAS is one of the measures of negative effects that assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).

    Time frame: within 24 hours post-dose

  7. Nausea VAS (Emax and TA_AUE)

    Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).

    Time frame: within 24 hours post-dose

  8. ARCI-A scale (Emax and TA_AUE)

    ARCI-A is measure of other stimulant effects. It is a set of 13 questions in which each question contributes to total score. Participants select 'False' / 'True' for response. One point given for each response that agrees with scoring direction, true items receive score of 1 if answer 'True', false items receive score of 1 if answer 'False'. No points if answer is opposite to scoring direction. Score range: 0 to 13, higher score indicated higher other subjective effects.

    Time frame: within 24 hours post-dose

  9. ARCI-BG scale (Emax and TA_AUE)

    ARCI-BG is measure of other subjective effects. It is a set of 13 questions in which each question contributes to total score. Participants select 'False' / 'True' for response. One point given for each response that agrees with scoring direction, true items receive score of 1 if answer 'True', false items receive score of 1 if answer 'False'. No points if answer is opposite to scoring direction. Score range: 0 to 13, higher score indicated higher other subjective effects.

    Time frame: within 24 hours post-dose

  10. Alertness/Drowsiness VAS (Emax and TA_AUE)

    Alertness/Drowsiness VAS is one of the measures of sedative effects. It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of "neither drowsy nor alert" (score of 50 mm), on the left with "very drowsy" (score of 0 mm) and on the right with "very alert" (score of 100 mm).

    Time frame: within 24 hours post-dose

  11. Agitation/Relaxation VAS (Emax and TA_AUE)

    Agitation/Relaxation VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm).

    Time frame: within 24 hours post-dose

  12. Any Effects VAS (Emax and TA_AUE)

    Any drug effects VAS is one of the measures of other subjective effects. It assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= definitely not) to 'extremely' (score of 100 mm= definitely so).

    Time frame: within 24 hours post-dose

  13. Drug Similarity VAS (score at 12 hours after study drug administration)

    Drug similarity VAS is one of the measures of other subjective effects. It assesses the similarity of the drug recently received by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm= not at all similar) to 'extremely' (score of 100 mm= very similar). Recently received drugs were compared with placebo, benzodiazepines, codeine/morphine, Tetrahydrocannabinol (THC), pseudoephedrine.

    Time frame: within 24 hours post-dose

  14. Safety and tolerability of EB-1020 as assessed by AEs

    Time frame: Up to 6 weeks

  15. Safety and tolerability of EB-1020 by laboratory assessments

    Time frame: Up to 6 weeks

  16. Safety and tolerability of EB-1020 as assessed by 12-lead ECGs

    Time frame: Up to 6 weeks

  17. Safety and tolerability of EB-1020 as assessed by vital signs

    Time frame: Up to 6 weeks

07

Study locations

1 site
  • Vince and Associates Clinical Research, Inc.
    Overland Park, Kansas 66212, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Jul 2014, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2014
First posted
May 22, 2014
StartActual
May 1, 2014
Primary completionActual
Jul 1, 2014
CompletionActual
Jul 1, 2014
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02144415
Responsible party
Sponsor
First posted
May 22, 2014
Start date
May 1, 2014
Primary completion
Jul 1, 2014
Completion
Jul 1, 2014
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Centanafadine

Start the discussion